Corpus Intelligence IC Memo — PHOENIX CHILDRENS HOSPITAL 2026-04-26 08:02 UTC
IC Memo — PHOENIX CHILDRENS HOSPITAL
Investment Committee Memorandum | AZ | 352 beds | Grade B | EBITDA uplift $92.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PHOENIX CHILDRENS HOSPITAL

CCN 033302 | MARICOPA, AZ | 352 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

PHOENIX CHILDRENS HOSPITAL is a 352-bed safety-net/medicaid heavy in MARICOPA, AZ with $1.26B in net patient revenue and a 6.0% operating margin. The hospital serves a payer mix of 0.5% Medicare, 63.6% Medicaid, and 35.8% commercial.

Thesis: Platform Growth. Our ML models identify $92.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 6.0% to 13.4% (+736bps).

Net Revenue HCRIS$1.26B
Current EBITDA COMPUTED$75.8M
Operating Margin COMPUTED6.0%
Occupancy HCRIS74.8%
Revenue / Bed COMPUTED$3.6M
Net-to-Gross HCRIS30.7%
Distress Probability ML53.5%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
28
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 6.0% places it above the state median. Among 28 size-comparable peers (176-704 beds), the median margin is -0.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (176-704), prioritizing same-state peers. 28 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PHOENIX CHILDRENS HOSPITAL (Target)AZ352$1.26B6.0%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
BANNER ESTRELLA MEDICAL CENTERAZ317$1.84B79.2%
BANNER BAYWOOD MEDICAL CENTERAZ323$1.39B79.1%
ST. JOSEPHS HOSPITAL & MEDICALAZ515$1.31B-17.7%
BANNER UNIVERSITY MEDICAL CENTAZ656$1.09B-5.9%
BANNER UNIVERSITY MED CENTER TAZ533$1.03B-4.6%
BANNER DESERT MEDICAL CENTERAZ629$833.1M12.6%
TUCSON MEDICAL CENTERAZ499$747.4M-2.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $92.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$26.4M+210bp18mo
Cost to Collect4.5%2.5%$25.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$24.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$15.3M+122bp9mo
Clean Claim Rate88.0%96.0%$803K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$26.4M
Cost to Collect
$25.1M
Denial Rate Reduction
$24.9M
A/R Days Reduction
$15.3M
Clean Claim Rate
$803K
Total EBITDA Uplift$92.4M
Current EBITDA$75.8M
+ RCM Uplift+$92.4M
Pro Forma EBITDA$168.2M
Current Margin6.0%
Pro Forma Margin13.4%
WC Released (1x)$48.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$116.6M$1.42B12.21x65.0%
Base (11x exit)10.0x11.0x$116.6M$1.60B13.76x68.9%
Bull Case9.0x11.0x$105.0M$1.95B18.55x79.3%
Bull (12x exit)9.0x12.0x$105.0M$2.16B20.53x83.0%
Bear Case11.0x10.0x$128.3M$924.3M7.20x48.4%
Bear (11x exit)11.0x11.0x$128.3M$1.06B8.25x52.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (63.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 53.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 28 hospitals with 176-704 beds
  • Same-state prioritization (n=29)
  • Comp margins: P25=-4.9% / P50=-0.9% / P75=6.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.